Intellia Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Good morning, everyone. My name is Gena Wang. I'm biotech analyst at the Barclays. Welcome to our fifth Gene Editing Gene Therapy Summit. It is my great pleasure to introduce our next speaker, John Leonard, President and Chief Executive Officer from Intellia. John, maybe I will hand over to you to give a brief overview, and we will dive into the Q&A.
Good morning, Gena. It's great to be here again. So that was fun to take your questions. By way of introduction, Intellia Therapeutics, I think the best way to think about us is what we call a full spectrum genome editing company. And by that, we mean a CRISPR/Cas9 and all of its various forms platform that is applied to both the in vivo and the ex vivo setting. And we try to do that in a modular way from both sides, emphasizing systemic delivery on the in vivo. And as you know from work we've done before, we're very, very enthusiastic about our liponanoparticle
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
